TSX:MDNA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. More Details


Snowflake Analysis

Flawless balance sheet with concerning outlook.

Share Price & News

How has Medicenna Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MDNA is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: MDNA's weekly volatility has decreased from 13% to 8% over the past year.


Market Performance


7 Day Return

6.1%

MDNA

4.9%

CA Biotechs

2.8%

CA Market


1 Year Return

298.5%

MDNA

80.8%

CA Biotechs

-0.3%

CA Market

Return vs Industry: MDNA exceeded the Canadian Biotechs industry which returned 76.8% over the past year.

Return vs Market: MDNA exceeded the Canadian Market which returned -0.5% over the past year.


Shareholder returns

MDNAIndustryMarket
7 Day6.1%4.9%2.8%
30 Day-1.5%24.7%10.0%
90 Day-7.3%25.8%5.7%
1 Year298.5%298.5%80.8%80.8%3.3%-0.3%
3 Year129.2%129.2%18.5%18.5%12.2%1.3%
5 Yearn/a6.0%6.0%49.1%26.2%

Long-Term Price Volatility Vs. Market

How volatile is Medicenna Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Medicenna Therapeutics undervalued compared to its fair value and its price relative to the market?

7.04x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MDNA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MDNA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MDNA is unprofitable, so we can't compare its PE Ratio to the XN Biotechs industry average.

PE vs Market: MDNA is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MDNA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MDNA is overvalued based on its PB Ratio (7x) compared to the CA Biotechs industry average (6.2x).


Next Steps

Future Growth

How is Medicenna Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

34.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MDNA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MDNA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MDNA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if MDNA's revenue is forecast to grow faster than the Canadian market.

High Growth Revenue: Insufficient data to determine if MDNA's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MDNA's Return on Equity is forecast to be very high in 3 years time (49%).


Next Steps

Past Performance

How has Medicenna Therapeutics performed over the past 5 years?

-17.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MDNA is currently unprofitable.

Growing Profit Margin: MDNA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MDNA is unprofitable, and losses have increased over the past 5 years at a rate of 17.6% per year.

Accelerating Growth: Unable to compare MDNA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MDNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.8%).


Return on Equity

High ROE: MDNA has a negative Return on Equity (-31.17%), as it is currently unprofitable.


Next Steps

Financial Health

How is Medicenna Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: MDNA's short term assets (CA$37.5M) exceed its short term liabilities (CA$1.6M).

Long Term Liabilities: MDNA's short term assets (CA$37.5M) exceed its long term liabilities (CA$13.0K).


Debt to Equity History and Analysis

Debt Level: MDNA is debt free.

Reducing Debt: MDNA has no debt compared to 5 years ago when its debt to equity ratio was 65.5%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MDNA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MDNA has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 19.2% each year.


Next Steps

Dividend

What is Medicenna Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MDNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MDNA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MDNA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MDNA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MDNA's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Fahar Merchant (63 yo)

4.58yrs

Tenure

CA$701,992

Compensation

Dr. Fahar Merchant, Ph.D. serves as the Chairman, Chief Executive Officer and President at A2 Acquisition Corp. Dr. Merchant has been President and Chief Executive Officer and Director of Medicenna Therape...


CEO Compensation Analysis

Compensation vs Market: Fahar's total compensation ($USD539.31K) is about average for companies of similar size in the Canadian market ($USD649.66K).

Compensation vs Earnings: Fahar's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Fahar Merchant
Founder4.58yrsCA$701.99k10.71%
CA$ 26.3m
Rosemina Merchant
Founder4.58yrsCA$513.89k10.71%
CA$ 26.3m
Elizabeth Williams
CFO & Corporate Secretary3.92yrsCA$370.50k0.011%
CA$ 26.6k
John Sampson
Chief Clinical Advisorno datano datano data
Martin Bexon
Head of Clinical Developmentno datano datano data
Samuel Denmeade
Scientific Advisor3.33yrsno datano data

4.3yrs

Average Tenure

63yo

Average Age

Experienced Management: MDNA's management team is considered experienced (4.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Fahar Merchant
Founder4.58yrsCA$701.99k10.71%
CA$ 26.3m
Rosemina Merchant
Founder4.58yrsCA$513.89k10.71%
CA$ 26.3m
John Geltosky
Director0.17yrno datano data
Karen Dawes
Independent Director1.17yrsCA$91.40k0.051%
CA$ 125.2k
Chandrakant Panchal
Lead Independent Directorno dataCA$97.90k0.0031%
CA$ 7.5k
Albert Beraldo
Non-Executive Independent Director4yrsCA$88.90k0.46%
CA$ 1.1m

4.0yrs

Average Tenure

67.5yo

Average Age

Experienced Board: MDNA's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 43.5%.


Top Shareholders

Company Information

Medicenna Therapeutics Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Medicenna Therapeutics Corp.
  • Ticker: MDNA
  • Exchange: TSX
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$245.484m
  • Shares outstanding: 49.00m
  • Website: https://www.medicenna.com

Number of Employees


Location

  • Medicenna Therapeutics Corp.
  • 2 Bloor Street West
  • 7th Floor
  • Toronto
  • Ontario
  • M4W 3E2
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MDNATSX (The Toronto Stock Exchange)YesCommon SharesCACADMar 2017
MDNANasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDMar 2017

Biography

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interle...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/26 23:47
End of Day Share Price2020/11/26 00:00
Earnings2020/09/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.